Related Experiment Video

Updated: Dec 5, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.0K

Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer

    Oncology (Williston Park, N.Y.)
    |October 15, 2020
    PubMed

    Insights

    Ovarian cancer remains a leading cause of death among gynecologic cancers. Despite decreasing mortality and incidence rates, new cases continue to be diagnosed, with most being aggressive epithelial types.

    Area of Science:

    • Gynecologic Oncology
    • Cancer Epidemiology
    • Public Health

    Background:

    • Ovarian cancer is the leading cause of death among gynecologic cancers in the U.S.
    • An estimated 13,940 deaths were expected in 2020.
    • The majority of ovarian cancers are epithelial, often high-grade serous adenocarcinomas, linked to poor prognosis.

    Purpose of the Study:

    • To summarize the epidemiological trends of ovarian cancer in the United States.
    • To highlight the burden of disease and recent changes in incidence and mortality.
    • To underscore the challenges associated with epithelial ovarian cancers.

    Main Methods:

    • Analysis of national cancer statistics.
    • Review of incidence and mortality data over specified periods.
    • Characterization of ovarian cancer subtypes.

    Main Results:

    • Ovarian cancer mortality decreased by 2.3% annually from 2008 to 2017.
    • Incidence rates declined by 1.6% per year from 2007 to 2016.
    • An estimated 21,750 new cases were projected for diagnosis in 2020.

    Conclusions:

    • While trends show a decline, ovarian cancer continues to represent a significant public health challenge.
    • Epithelial ovarian cancers, particularly high-grade serous types, present a poor prognosis and limited known risk factors.
    • Continued research and public health efforts are crucial for addressing ovarian cancer mortality and incidence.

    More Related Videos

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

    Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

    Published on: November 2, 2014

    12.6K
    Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

    Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

    Published on: August 21, 2013

    15.3K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.3K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.6K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    5.4K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.7K
    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    9.6K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.4K